{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:40Z","timestamp":1790741620358,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"DOI":"10.1007\/s10565-026-10183-2","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:20:52Z","timestamp":1775686852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanism of uptake and toxicity of a BCMA antibody drug conjugate with a MMAF payload by nonantigen expressing cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Carla","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Sohanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"H\u00f6gg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-3933","authenticated-orcid":false,"given":"Eliot","family":"McKinley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9959-4667","authenticated-orcid":false,"given":"Elena","family":"Koudouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-1119","authenticated-orcid":false,"given":"Edward J.","family":"Sayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-8905","authenticated-orcid":false,"given":"Arwyn T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0250-7852","authenticated-orcid":false,"given":"Peter","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"10183_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144942","volume":"10","author":"R Ard","year":"2015","unstructured":"Ard R, Mulatz K, Pomoransky JL, Parks RJ, Trinkle-Mulcahy L, Bell JC, et al. Regulation of macropinocytosis by diacylglycerol kinase \u03b6. PLoS One. 2015;10:e0144942. https:\/\/doi.org\/10.1371\/journal.pone.0144942.","journal-title":"PLoS One"},{"key":"10183_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01015-w","volume":"11","author":"P Catal\u00e0","year":"2021","unstructured":"Catal\u00e0 P, Groen N, Dehnen JA, Soares E, van Velthoven AJH, Nuijts R, et al. Single cell transcriptomics reveals the heterogeneity of the human cornea to identify novel markers of the limbus and stroma. Sci Rep. 2021;11:21727. https:\/\/doi.org\/10.1038\/s41598-021-01015-w.","journal-title":"Sci Rep"},{"key":"10183_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36567-6","volume":"13","author":"P Catal\u00e0","year":"2023","unstructured":"Catal\u00e0 P, Groen N, LaPointe VLS, Dickman MM. A single-cell RNA-seq analysis unravels the heterogeneity of primary cultured human corneal endothelial cells. Sci Rep. 2023;13:9361. https:\/\/doi.org\/10.1038\/s41598-023-36567-6.","journal-title":"Sci Rep"},{"key":"10183_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495137","author":"H Chen","year":"2024","unstructured":"Chen H, He G, Huang J, Hu L, Ma J. Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1495137.","journal-title":"Front Immunol"},{"key":"10183_CR5","unstructured":"ClinicalTrials.gov. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20). 2023. https:\/\/clinicaltrials.gov\/study\/NCT05714839. Accessed 3 Jul 2024."},{"key":"10183_CR6","unstructured":"ClinicalTrials.gov. Phase 1\/\u200b2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05145816. Accessed 26 March 2026."},{"key":"10183_CR7","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u201312. https:\/\/doi.org\/10.1016\/S2352-3026(23)00243-0.","journal-title":"Lancet Haematol"},{"key":"10183_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"key":"10183_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hem3.70152","volume":"9","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Updated results from phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. HemaSphere. 2025;9:846\u20137. https:\/\/doi.org\/10.1002\/hem3.70152.","journal-title":"HemaSphere"},{"key":"10183_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177","volume":"29","author":"GK Dy","year":"2024","unstructured":"Dy GK, Farooq AV, Kang JJ. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist. 2024;29:e1435. https:\/\/doi.org\/10.1093\/oncolo\/oyae177.","journal-title":"Oncologist"},{"key":"10183_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8.","journal-title":"Ophthalmol Ther"},{"key":"10183_CR12","unstructured":"GSK. Blenrep approved by US FDA for use in treatment of relapsed\/refractory multiple myeloma. 2025. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma\/.\u00a0Accessed 23 Oct 2025."},{"key":"10183_CR13","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/blood-2023-178009","volume":"142","author":"VTM Hungria","year":"2023","unstructured":"Hungria VTM, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed\/refractory multiple myeloma in DREAMM-3. Blood. 2023;142:3357. https:\/\/doi.org\/10.1182\/blood-2023-178009.","journal-title":"Blood"},{"key":"10183_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"key":"10183_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:1067\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(25)00330-4.","journal-title":"Lancet Oncol"},{"key":"10183_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184088","author":"M Kleber","year":"2021","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-a promising key to therapy. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10184088.","journal-title":"J Clin Med"},{"key":"10183_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jtos.2019.10.004","volume":"18","author":"J Kwon","year":"2020","unstructured":"Kwon J, Surenkhuu B, Raju I, Atassi N, Mun J, Chen Y-F, et al. Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease. Ocul Surf. 2020;18:80\u201397. https:\/\/doi.org\/10.1016\/j.jtos.2019.10.004.","journal-title":"Ocul Surf"},{"key":"10183_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jamaophthalmol.2025.1008","volume":"143","author":"V Lee","year":"2025","unstructured":"Lee V, Hultcrantz M, Petrone S, Lewis EW, Banna H, Lichtman E, et al. Characterization of belantamab mafodotin\u2013induced corneal changes in patients with multiple myeloma. JAMA Ophthalmol. 2025;143:507\u201314. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.1008.","journal-title":"JAMA Ophthalmol"},{"key":"10183_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","volume":"12","author":"ES Lindgren","year":"2024","unstructured":"Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, et al. Incidence and mitigation of corneal pseudomicrocysts induced by antibody\u2013drug conjugates (ADCs). Curr Ophthalmol Rep. 2024;12:13\u201322. https:\/\/doi.org\/10.1007\/s40135-024-00322-5.","journal-title":"Curr Ophthalmol Rep"},{"key":"10183_CR20","doi-asserted-by":"publisher","first-page":"E978","DOI":"10.1073\/pnas.1311029111","volume":"111","author":"M Maekawa","year":"2014","unstructured":"Maekawa M, Terasaka S, Mochizuki Y, Kawai K, Ikeda Y, Araki N, et al. Sequential breakdown of 3-phosphorylated phosphoinositides is essential for the completion of macropinocytosis. Proc Natl Acad Sci U S A. 2014;111:E978\u201387. https:\/\/doi.org\/10.1073\/pnas.1311029111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10183_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1425617.","journal-title":"Front Pharmacol"},{"key":"10183_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01172-5","volume":"14","author":"K Marquant","year":"2021","unstructured":"Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021;14:159. https:\/\/doi.org\/10.1186\/s13045-021-01172-5.","journal-title":"J Hematol Oncol"},{"key":"10183_CR23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016949","author":"M-V Mateos","year":"2025","unstructured":"Mateos M-V, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016949.","journal-title":"Blood Adv"},{"key":"10183_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/cimb43030088","volume":"43","author":"H Mizuguchi","year":"2021","unstructured":"Mizuguchi H, Miyamoto Y, Terao T, Yoshida H, Kuroda W, Kitamura Y, et al. Signaling pathway of histamine H(1) receptor-mediated histamine H(1) receptor gene upregulation induced by histamine in U-373 MG cells. Curr Issues Mol Biol. 2021;43:1243\u201354. https:\/\/doi.org\/10.3390\/cimb43030088.","journal-title":"Curr Issues Mol Biol"},{"key":"10183_CR25","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941\u201355. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0035.","journal-title":"Mol Cancer Ther"},{"key":"10183_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.30760","volume":"6","author":"N Nandi","year":"2017","unstructured":"Nandi N, Tyra LK, Stenesen D, Kr\u00e4mer H. Stress-induced Cdk5 activity enhances cytoprotective basal autophagy in Drosophila melanogaster by phosphorylating acinus at serine437. Elife. 2017;6:e30760. https:\/\/doi.org\/10.7554\/eLife.30760.","journal-title":"Elife"},{"key":"10183_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1083\/jcb.201604032","volume":"215","author":"JK Park","year":"2016","unstructured":"Park JK, Peng H, Katsnelson J, Yang W, Kaplan N, Dong Y, et al. MicroRNAs-103\/107 coordinately regulate macropinocytosis and autophagy. J Cell Biol. 2016;215:667\u201385. https:\/\/doi.org\/10.1083\/jcb.201604032.","journal-title":"J Cell Biol"},{"key":"10183_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1167\/iovs.16-21111","volume":"58","author":"H Peng","year":"2017","unstructured":"Peng H, Park JK, Lavker RM. Autophagy and macropinocytosis: keeping an eye on the corneal\/limbal epithelia. Invest Ophthalmol Vis Sci. 2017a;58:416\u201323. https:\/\/doi.org\/10.1167\/iovs.16-21111.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10183_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/15548627.2017.1287658","volume":"13","author":"H Peng","year":"2017","unstructured":"Peng H, Park JK, Lavker RM. Eyeing autophagy and macropinocytosis in the corneal\/limbal epithelia. Autophagy. 2017;13(5):975\u20137. https:\/\/doi.org\/10.1080\/15548627.2017.1287658.","journal-title":"Autophagy"},{"key":"10183_CR30","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","volume":"105","author":"R Popat","year":"2020","unstructured":"Popat R, Warcel D, O\u2019Nions J, Cowley A, Smith S, Tucker WR, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020;105:e261\u20133. https:\/\/doi.org\/10.3324\/haematol.2019.235937.","journal-title":"Haematologica"},{"key":"10183_CR31","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.231639","author":"G Salloum","year":"2019","unstructured":"Salloum G, Jakubik CT, Erami Z, Heitz SD, Bresnick AR, Backer JM. PI3K\u03b2 is selectively required for growth factor-stimulated macropinocytosis. J Cell Sci. 2019. https:\/\/doi.org\/10.1242\/jcs.231639.","journal-title":"J Cell Sci"},{"key":"10183_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00070","author":"MG Sugiyama","year":"2019","unstructured":"Sugiyama MG, Fairn GD, Antonescu CN. Akt-ing up just about everywhere: compartment-specific Akt activation and function in receptor tyrosine kinase signaling. Front Cell Dev Biol. 2019. https:\/\/doi.org\/10.3389\/fcell.2019.00070.","journal-title":"Front Cell Dev Biol"},{"key":"10183_CR33","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2018.0146","author":"JA Swanson","year":"2018","unstructured":"Swanson JA, King JS. The breadth of macropinocytosis research. Philos Trans R Soc Lond B Biol Sci. 2018. https:\/\/doi.org\/10.1098\/rstb.2018.0146.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10183_CR34","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187\u201399. https:\/\/doi.org\/10.2217\/imt.15.77.","journal-title":"Immunotherapy"},{"key":"10183_CR35","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338. https:\/\/doi.org\/10.1182\/blood-2013-10-535088.","journal-title":"Blood"},{"key":"10183_CR36","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225\u201336. https:\/\/doi.org\/10.1182\/blood-2016-01-691162.","journal-title":"Blood"},{"key":"10183_CR37","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.cellsig.2014.02.014","volume":"26","author":"EJ Tisdale","year":"2014","unstructured":"Tisdale EJ, Shisheva A, Artalejo CR. Overexpression of atypical protein kinase C in HeLa cells facilitates macropinocytosis via Src activation. Cell Signal. 2014;26:1235\u201342. https:\/\/doi.org\/10.1016\/j.cellsig.2014.02.014.","journal-title":"Cell Signal"},{"key":"10183_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136963","volume":"25","author":"Y Wu","year":"2024","unstructured":"Wu Y, Hu X, Wei Z, Lin Q. Cellular regulation of macropinocytosis. Int J Mol Sci. 2024;25:6963.","journal-title":"Int J Mol Sci"},{"key":"10183_CR39","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018;78:2115\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3202.","journal-title":"Cancer Res"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-026-10183-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:54:52Z","timestamp":1783468492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10565-026-10183-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10183"],"URL":"https:\/\/doi.org\/10.1007\/s10565-026-10183-2","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required for this study as commercially available cell lines were investigated in vitro.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"CN, CT, GS, TH, JK, EM, and LW are employees of and hold financial equities in GSK. EK, EJS, ATJ, and PW report no conflicts of interest. Data were presented in part at the Society of Toxicology Annual Meeting and ToxExpo 2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"86"}}